Stud

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stud

What is Stud? Overview and Quick Facts

Property Description
Active Ingredient Lidocaine Hydrochloride
Form Topical Solution / Metered-Dose Spray
Pharmacological Class Local Anesthetic (Amide-Type)
General Purpose To create a temporary loss of localized sensation
Origin Synthetic Compound
Key Differentiating Feature Marketed specifically as a metered-dose spray for use by adult males

What is Stud and What Pharmacological Class Does it Belong To?

The medicine Stud is a brand-name, specialized topical preparation whose primary component is the active ingredient Lidocaine Hydrochloride. This substance is formally classified as an amide-type Local Anesthetic, a pharmacological class of agents used to induce a reversible, localized numbing effect.

Lidocaine Hydrochloride is a synthetic compound, distinguishing it chemically from older anesthetic classes. The brand Stud is particularly known for its positioning toward adult males, differentiating it from generic Lidocaine preparations. Understanding its identity as a local anesthetic establishes its core purpose: to temporarily interrupt the transmission of sensation signals, such as those related to touch or discomfort, without affecting systemic physiology.

Composition, Drug Form, and Primary Function

This pharmaceutical is prepared as a topical solution delivered via a metered-dose spray, a mechanism designed for consistent and precise application to the skin surface. The formulation features the Lidocaine Hydrochloride active ingredient within a compatible solvent system that facilitates rapid action.

The specific drug form, an aqueous solution administered topically, allows for an external route of administration, creating a localized, temporary loss of sensation. Topical Lidocaine functions by stabilizing the neuronal membrane, which temporarily blocks nerve signals. The product's primary function is thus to provide a focused, short-term reduction in sensitivity on the treated surface, utilizing a reliable delivery profile.

Regulatory References

  1. Lidocaine - StatPearls - NCBI Bookshelf
  2. LIDOCAINE HYDROCHLORIDE solution - DailyMed - NIH

What side effects are possible with Stud?

Possible Side Effects and Safety Information

Adverse reactions associated with the approved, genuine formulation of Stud are generally localized and related to the topical anesthetic, Lidocaine.

Key Adverse Reactions

System-Organ Class Common Reactions Clinically Significant Reactions (Systemic)
Skin & Subcutaneous Tissue Rash, irritation, burning, stinging, or itching at the application site. Hypersensitivity reactions (allergic reactions).
Nervous System Reduced tactile sensation (intended effect). Dose-dependent systemic toxicity: Dizziness, somnolence, confusion, or convulsions.
Cardiovascular System None reported under normal use. Dose-dependent systemic toxicity: Bradycardia or hypotension, leading to cardiovascular collapse in rare, severe cases.

Serious Safety Considerations

The most significant risks are associated with systemic toxicity from excessive application or use on broken/inflamed skin, which can lead to dangerously high blood concentrations of the active ingredient. Additionally, post-market surveillance by regulatory agencies like the FDA has issued warnings concerning unapproved, adulterated products sold under the "Stud" name (e.g., in supplement form) that contained undeclared prescription drug ingredients, such as Sildenafil. These adulterated products pose a severe, life-threatening cardiovascular risk, particularly to users taking nitrate drugs, due to the potential for precipitating severe hypotension.

Restrictions and Monitoring

  • Contraindications: Use is contraindicated for individuals with known hypersensitivity or allergy to local anesthetics of the amide type (e.g., Lidocaine). It must not be applied to broken or inflamed skin.
  • Dose-related Risk: The risk of systemic adverse effects is directly proportional to the extent of systemic exposure; therefore, use beyond the recommended amount or frequency increases the risk of serious complications.
  • Population-Specific Caution: Individuals with severe hepatic (liver) or renal (kidney) impairment may be at higher risk for toxic blood concentrations due to impaired elimination and should consult a healthcare provider before use. The product is also restricted from use when a sexual partner is pregnant.

Regulators globally encourage the reporting of unexpected or serious adverse events to their respective pharmacovigilance programs to ensure continuous safety monitoring of medicinal products.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for the active ingredient, Lidocaine Hydrochloride, is defined by documented systemic effects primarily impacting the Central Nervous System (CNS) and the Cardiovascular System (CVS).

Documented Manifestations and Severe Outcomes

Initial overdose manifestations, typically associated with high plasma concentrations, may include lightheadedness, dizziness, tinnitus, and numbness of the tongue. As systemic toxicity progresses, regulatory documents list severe, life-threatening outcomes such as seizures and profound CNS depression, alongside serious CVS effects like bradycardia, ventricular arrhythmias, and potential cardiovascular collapse.

Required Emergency Actions

Any manifestation suggesting systemic toxicity mandates that the individual seek immediate medical attention. In cases involving severe outcomes such as respiratory arrest or cardiovascular collapse, contacting emergency services is required. Management of overdose is symptomatic and supportive, encompassing continuous ECG monitoring and securing the patient's airway, as no specific antidote is known.

Regulatory warnings indicate an increased risk of toxicity for elderly patients and those with severe hepatic impairment due to reduced drug clearance.

Therapeutic Uses of Stud

Stud, a topical solution, is relevant when supportive symptom management is appropriate, providing short-term symptomatic assistance for symptoms related to heightened physiological activity.

Management of Premature Ejaculation and Ejaculatory Control

Stud is commonly used across conditions presenting with acute episodes of Premature Ejaculation (PE). It is relevant for easing symptoms related to heightened physiological activity that create noticeable physiological strain and interfere with daily comfort. By assisting with the symptomatic management of this functional concern, it contributes to easing the overall symptom load and may assist with maintaining functional stability.

Addressing Localized Genital Hypersensitivity

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns. This supportive relief is relevant for managing symptom clusters that may become intense or disruptive during intimate relations. The product is used in areas where short-term symptom management is appropriate, which contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities. The primary indications addressed include PE, over-rapid ejaculation, and localized hypersensitivity.

“This application helps address symptom clusters that may become intense or disruptive during intimate relations.”


Quick Fact: Relief for Localized Discomfort Stud is primarily relevant for easing symptoms related to localized discomfort and heightened physiological activity, which supports patients in managing functional strain during episodes of Premature Ejaculation.

Regulatory References

  1. Label: MALE GENITAL DESENSITIZER STUD 100- lidocane spray, metered - DailyMed

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult Males (18 years and older).

Populations for whom use is not recommended (if applicable): Children and adolescents (under 18 years); Older adults with severe debilitation or acute illness.

Populations for whom use is contraindicated:

  • Patients with a known history of hypersensitivity to Lidocaine or other amide-type local anesthetics.
  • Users whose partner is pregnant.

Age-related eligibility rules: Use is restricted to adults (18+); use in pediatric populations is not established or recommended.

Condition-specific eligibility rules: Conditional caution is required for patients with severe hepatic disease, cardiac conduction abnormalities, or severely damaged/non-intact skin at the application site.

Pregnancy and lactation eligibility status (if explicitly documented): Contraindicated if the user’s partner is pregnant; caution is advised regarding exposure to a breastfeeding partner.

Eligibility-related restrictions: Use is restricted on broken or inflamed skin; must not be used near external heat sources.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication (e.g., Hypersensitivity); Conditional Restriction (e.g., Hepatic Impairment); Use Not Established (e.g., Pediatric).

Regulatory basis (EMA / FDA / etc.): FDA, EMA, and National Medicines Authorities.

Eligibility-context constraints (as defined in official documents): Limited to specific Adult Age Group; Prohibited in cases of Hypersensitivity History; Restricted by Application Site Integrity.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in patients with a history of sensitivity to Lidocaine or the amide-type local anesthetic class.
  • The medicine is not established or recommended for use in patients under 18 years of age.
  • Use is restricted in patients with severe hepatic or cardiac impairment.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define eligibility by establishing the medicine's use for adult males and imposing strict exclusion criteria. Absolute non-eligibility is mandated for individuals with relevant allergies and in specific partner pregnancy scenarios. Conditional use applies to populations with pre-existing conditions that could lead to heightened systemic absorption and toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Classification Details from Official Regulatory Documents
Medicinal Product Categories Local Anesthetics, Class I and III Antiarrhythmic Drugs, CYP1A2 and CYP3A4 Inhibitors, Oxidizing Agents, Nonselective Beta-blockers, H2-receptor Antagonists.
Mechanistic Basis Pharmacokinetic interaction via reduced clearance, stemming from inhibition of CYP enzymes and decreased hepatic blood flow. Pharmacodynamic interaction via additive toxic effects.
Population Notes Interaction risk, leading to accumulation, is officially noted as more significant in patients with severe hepatic disease, elderly patients, and acutely ill patients due to impaired drug clearance.

Resulting Interaction Structure

Official regulatory documents define the product's interaction structure primarily through changes in systemic exposure and cumulative toxicity risk.

  • Co-administration with CYP1A2 and CYP3A4 inhibitors (e.g., Fluvoxamine, Ciprofloxacin) may increase systemic exposure (AUC and Cmax) of Lidocaine and its active metabolite, MEGX, by reducing its metabolic clearance.
  • The risk of additive toxic effects is documented when used with Other Local Anesthetics or Class I/III Antiarrhythmic Drugs (e.g., Dronedarone, Amiodarone).
  • Use with Oxidizing Agents (substances associated with methemoglobinemia risk) may increase the likelihood of developing methemoglobinemia.
  • Cimetidine and Beta-blockers (e.g., Propranolol) can officially reduce hepatic blood flow, potentially leading to drug accumulation under high-dose or prolonged application conditions.
  • Grapefruit juice is documented as a substance that can interact with CYP enzymes and may alter plasma concentrations.

Mechanism of Action

The mechanism of action for the active ingredient is based on its precise, localized ability to inhibit the propagation of electrical signals in peripheral nerves. The mechanism is confined to the specific anatomical location of application.

Targeted Blockade of Peripheral Sodium Channels

This domain centers on the molecular interaction where the drug acts as an inhibitor, binding directly within the pore of Voltage-Gated Sodium Channels ( VGSCs) on sensory nerve membranes. This physical obstruction prevents the necessary influx of sodium ions ( Na^+), which are critical for generating a nerve impulse. The mechanism is characterized as use-dependent, as the drug preferentially blocks channels that are open or rapidly cycling, exhibiting enhanced block efficiency in actively transmitting nerves.


Inhibition of the Afferent Signaling Cascade

By preventing the influx of Na^+ ions, the drug achieves neuronal membrane stabilization, thereby increasing the electrical threshold required for the nerve to fire. The resulting physiological consequence is the functional inability of the nerve to propagate the action potential (electrical signal) from the peripheral application site towards the central nervous system. This functional arrest of afferent sensory signaling is the sole physiological driver leading to the alteration of localized sensory nerve function.

Dosage and Administration Information

Official Administration Guidelines for Stud

The usage of Stud, a Lidocaine topical solution, follows specific instructions defining the route, quantity, and timing of administration.


Administration Scope

Category Official Instruction
Route of Administration Application is strictly topical to the external skin surface.
Dosing Schedule The standard application range is 3 to 8 sprays per use. Each metered spray delivers 10 mg of the active ingredient. A maximum of 10 sprays is permitted for a single application, with the total daily dose restricted to 24 sprays.
Frequency and Timing The product is used on an as-needed, episodic basis, with administration limited to not more than 3 times daily within a 24-hour period. Application must occur 5 to 10 minutes prior to intercourse.
Population Rules The established instructions apply specifically to Adult Males.
Special Procedures The product is for external use only and must be washed off immediately following the activity.

Protocol Summary

Administration method type is defined as a topical spray. The frequency pattern is designated as as-needed (episodic).

The administration protocol for Stud is structured around a precise 5 to 10-minute pre-activity timing requirement and an immediate post-activity wash-off condition. This structure ensures the product is utilized according to its intended short-term, localized application model, adhering to all dosing maximums.

Recent Clinical Evidence

Research evidence / Overview of Studies for Stud

Evidence for Use in Premature Ejaculation (PE)

The research foundation for Stud, a topical solution studied for symptoms associated with Premature Ejaculation (PE), primarily consists of Randomized Controlled Trials (RCTs). These are often double-blind, multi-centre studies, which are considered to provide a high level of evidence structure for clinical evaluation. Research has explored the medicine's application for both lifelong (primary) PE and acquired PE.

Studies examined how symptoms change over time by monitoring objective measures like Intravaginal Ejaculatory Latency Time (IELT) and patient-reported outcomes (PROs). The PROs described perceived discomfort, including measures of ejaculatory control, sexual satisfaction for the patient and their partner, and the level of distress associated with the condition.

Study Design and Outcomes Measured

The trials were conducted during periods of increased symptom activity, with core RCTs generally conducting evaluations over periods up to 12 weeks. This design helped researchers compare the measurements taken in the study groups receiving the preparation with those receiving an inactive placebo. The evidence contributes to understanding symptom patterns by tracking objective measures like IELT and subjective measures like self-reported impact. The specific formulation and delivery method was studied by tracking outcomes in research contexts involving fluctuating or unstable symptoms typical of PE.

Research Gaps and What Remains Uncertain

While the existing research contributes to the broader evidence landscape, long-term outcomes are not fully established, as the follow-up durations were limited in the most rigorous studies. Data for maintenance of effects over many months or years remains insufficient. Furthermore, subgroup findings are uncertain for certain populations.

Limited information is derived from studies assessing outcomes in elderly males (age ge 65 years), and comparative evidence is limited for men in non-monogamous or non-heterosexual relationships. Observational studies evaluating daily-life functioning describe that patients reported challenges with sustained adherence in these settings, highlighting areas where more research is needed.

Frequently Asked Questions (FAQ)

Common questions about Stud (FAQ)


Q: What should I do if I miss a dose of Stud?

According to the official product information, Stud is intended for as-needed, episodic use immediately prior to activity. Because of this specific pre-activity timing, the concept of a 'missed dose' that would apply to a regularly scheduled medication is not relevant to this product.


Q: Are there any specific foods or drinks that should be avoided when taking Stud?

Regulatory documents advise that Grapefruit juice may potentially alter the concentration of the active ingredient in the bloodstream by affecting certain liver enzymes. Beyond Grapefruit juice, other general foods or drinks are not specifically listed for avoidance in the official product information.


Q: Is it common for people to experience changes in mood while on Stud?

Official documentation reports that systemic toxicity from using too much of the product may cause central nervous system effects such as dizziness, somnolence (drowsiness), or confusion. However, changes in mood are not listed among the commonly reported side effects in the official studies.


Q: What should be done in the event of an overdose of Stud?

Symptoms of systemic toxicity from using too much of the product include serious effects like dizziness, confusion, or convulsions. The official administration procedure describes the need for the product to be washed off immediately following activity. These symptoms are considered serious events that warrant immediate medical evaluation.


Q: Is Stud known to be addictive or habit-forming?

The active ingredient in Stud is an amide-type local anesthetic. Official regulatory documents indicate that the product is not classified as an addictive or habit-forming controlled substance.


Q: What happens in the body when Stud starts to wear off?

The effect of the medicine starts to wear off as the body begins to process and eliminate the active ingredient, primarily through the liver. This reverses the temporary nerve blockade, which is how the localized sensation returns. The elimination half-life of the active ingredient is typically 1.5 to 2.0 hours.


Q: How long do the effects of a single dose of Stud typically last?

The product is applied 5 to 10 minutes prior to intercourse and must be washed off immediately following the activity. While the specific duration of the anesthetic effect can vary, the official usage guidelines limit the application period to the time immediately surrounding the activity.


Q: How does the body process or eliminate Stud?

The active ingredient is mainly processed and metabolized by the liver using specific enzymes. The official label notes that individuals with severe hepatic (liver) or renal (kidney) impairment are considered to be at a higher risk of systemic accumulation due to impaired elimination.


Q: Can Stud be used by people who have a history of heart issues?

Use of the medicine is subject to conditional restriction for patients with pre-existing conditions that may increase systemic risk, including cardiac conduction abnormalities. This is because excessive use leading to systemic toxicity may lead to rare but serious cardiovascular effects, such as a drop in heart rate (bradycardia) or blood pressure (hypotension).


Q: Do studies suggest Stud loses its effect over time (tolerance)?

Studies and official information indicate that long-term outcomes and the maintenance of effects over many months or years are not fully established in the most rigorous clinical studies. Therefore, data on the development of tolerance is considered insufficient.


Q: What official warnings are associated with Stud use?

Key warnings are related to the risk of systemic toxicity from using too much of the product or applying it to broken skin. Regulatory agencies also warn against unapproved, adulterated products sold under the brand name 'Stud' that may contain undeclared prescription drugs like Sildenafil, which poses a severe cardiovascular risk.


Q: Does Stud require any special storage conditions, like refrigeration?

Official labeling requires this medication to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Refrigeration is not required.


Q: Are there any restrictions on driving or operating machinery while using Stud?

Official documentation notes that systemic toxicity from overdose can cause effects like dizziness, somnolence, and confusion. Regulatory warnings are generally in place when these types of central nervous system effects are reported, as they may impact activities requiring full mental alertness.


Q: Are headaches a frequent side effect of Stud?

Headache has been reported as an adverse event associated with the use of the active ingredient. However, it is not listed among the most commonly reported localized reactions in the primary official clinical studies for this product.


Q: What is the difference between the active ingredient in Stud and its inactive ingredients?

The active ingredient, Lidocaine Hydrochloride, is the synthetic substance that produces the temporary loss of localized sensation. The inactive ingredients are components of the topical solution that facilitate the drug’s correct delivery, stability, and absorption into the skin surface.


Q: Do regulatory agencies list Stud as having a high risk of drug-drug interactions?

Regulatory documents define a risk of interaction based on the co-administration of specific drugs, such as certain CYP enzyme inhibitors and Class I and III Antiarrhythmic Drugs. These interactions may lead to increased systemic exposure or additive toxic effects on the body.


Q: Is there a specific time of day Stud should be taken?

There is no restriction on the time of day. Official guidelines state that the product is used on an as-needed, episodic basis, with application required specifically 5 to 10 minutes prior to intercourse.


Q: Can Stud be used safely with common antibiotics?

Some medications within the broad class of antibiotics (such as Ciprofloxacin) are listed as CYP1A2 inhibitors, which can potentially increase the systemic exposure of the active ingredient. Additionally, some antibiotics have been linked to an increased risk of a rare blood condition called methemoglobinemia.


Q: Can people with liver impairment use Stud?

Individuals with severe hepatic (liver) impairment are noted in official documents as being at a higher risk for toxic blood concentrations due to the active ingredient's clearance being impaired. This population is subject to conditional restriction for use.


Q: What is the difference between taking Stud as needed versus regularly?

Official guidelines define the product as used on an as-needed, episodic basis, limited to not more than 3 times daily. This usage method prevents the chronic, scheduled administration associated with regularly taken medicines.


Q: Are children or adolescents permitted to use Stud, according to official guidelines?

Official guidelines state that use is restricted to adult males (18 years and older). The medicine is not established or recommended for use in pediatric populations, which includes children and adolescents under 18 years of age.


How should Stud be stored and disposed of?

How to Store and Dispose of Stud?

This medication must be stored according to labeled requirements to maintain its stability and effectiveness. The official labeled storage condition is Controlled Room Temperature, typically 20, C to 25, C (68, F to 77, F). The product must be protected from moisture and kept in its original container with the lid tightly sealed when not in use. It is critical to keep the medication, along with all others, out of the sight and reach of children and, where required by regulation, in a locked storage area.

Disposal must follow local and federal regulations to prevent environmental risk. Unused or expired medication should be disposed of via drug take-back programs or, if unavailable, by following documented safe disposal methods, which may involve mixing the product with an undesirable substance and discarding it in the trash. The product should not be allowed to enter drains, the sewage system, or water bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stud found in:

A-Z Index: